The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Leadership - Akamis Bio; Kinnate Biopharma; Kura Oncology; Pangea
Stock and Other Ownership Interests - Kinnate Biopharma; Primmune Therapeutics
Consulting or Advisory Role - Adagene; Astellas Pharma; Cidara; Eisai; Genmab; Gilboa Therapeutics; iTEOS Therapeutics; Lilly O.; Merck; MSD; Nectin Therapeutics; Novartis; Nykode Therapeutics; Pangea; PCI Biotech; Replimune; Roche; SOTERIA Precision Medicine; Tempus; Viracta Therapeutics
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
 
Kevin Joseph Harrington
Honoraria - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Codiak Biosciences (Inst); Inzen Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Oncolys BioPharma (Inst); Pfizer (Inst); Replimune (Inst); Scenic Biotech
Consulting or Advisory Role - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Inzen Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Oncolys BioPharma (Inst); Replimune (Inst)
Speakers' Bureau - BMS (Inst); Merck Serono (Inst); MSD (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Replimune (Inst)
 
Ezra Cohen
No Relationships to Disclose
 
Dan Paul Zandberg
Consulting or Advisory Role - Blueprint Medicines; Macrogenics; Merck; Prelude Therapeutics
Research Funding - Aduro Biotech (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst)
 
Terry A. Day
No Relationships to Disclose
 
Jessica Lyn Geiger
Consulting or Advisory Role - Astellas Pharma; Exelixis; Merck; Regeneron
Research Funding - Alkermes (Inst); Genentech/Roche (Inst); Merck (Inst); Merck Serono (Inst); Merck Serono (Inst); Regeneron (Inst)
 
Marc Oliva
Honoraria - Bristol-Myers Squibb/Pfizer; Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology; Transgene
Consulting or Advisory Role - Merck KGaA
Research Funding - ALX Oncology (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Merck; MSD Oncology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology
Other Relationship - Merck; MSD Oncology
 
Ricard Mesia
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Merck KGaA; MSD; Nanobiotix; Roche; Seagan
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Merck KGaA; MSD
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
David Michael Cohan
Employment - Replimune
Stock and Other Ownership Interests - Replimune
Travel, Accommodations, Expenses - Replimune